Morgan Stanley 24th Annual Global Healthcare Conference
Logotype for Elanco Animal Health Incorporated

Elanco Animal Health (ELAN) Morgan Stanley 24th Annual Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Elanco Animal Health Incorporated

Morgan Stanley 24th Annual Global Healthcare Conference summary

15 Sep, 2026

Market trends and industry outlook

  • Pet health market is projected to grow from $40B to $60B over the next decade, driven by durable demand and innovation.

  • Pet spending remains resilient, with 80% of companies in the sector growing in the first half of the year.

  • The farm animal segment is benefiting from global protein demand, with dairy and poultry as key growth drivers and a five-year beef shortage impacting the market.

  • Omni-channel and online purchasing are increasing, with 40% of pet care now subscription-based, boosting compliance and sales.

  • The company is well-positioned for continued growth, with innovation and commercial execution as core strategies.

Product innovation and portfolio performance

  • Innovation is the main growth driver, especially for products like Zenrelia, Quattro, and Befrena, which are gaining share and expanding clinic penetration.

  • The derm and parasiticide markets are growing, with differentiated products enabling price increases and new clinic additions.

  • Vaccine and therapeutic portfolios are seeing a halo effect from innovation, leading to increased market share and stability.

  • Credelio Quattro is expected to become the largest brand family, with international launches planned for next year.

  • Zenrelia and Befrena are driving growth in the derm market, with strong adoption and plans for further label improvements.

Financial performance and guidance

  • Pricing accelerated in July and August, with broad-based increases across pharma and pet segments.

  • Organic growth targets have been raised, with innovation-led growth expected to continue through 2027 and beyond.

  • Margin improvements are anticipated through fixed cost leverage and the Ascend program, targeting 60% gross margins.

  • Investments in manufacturing and R&D are expected to normalize after 2026, with no anticipated capacity gaps.

  • The company remains opportunistic in talent acquisition, leveraging market disruptions to strengthen its team.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more